Bulletin from Annual General Meeting in Isofol Medical AB (publ) held on June 23, 2021
Today on June 23, 2021 in Gothenburg – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), held […]
Regulatory
Isofol raises SEK 500 million in oversubscribed rights issue and exercised over-allotment option
GOTHENBURG, Sweden, June 14, 2021 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the
Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 400 million
GOTHENBURG, Sweden, May 25, 2021 – Isofol Medical AB’s (publ), (Nasdaq First North Premier Growth Market: ISOFOL), (“Isofol or the
Isofol’s Board of Directors resolves on a fully guaranteed preferential rights issue of approximately SEK 400 million
GOTHENBURG, Sweden, May 18, 2021 – Isofol Medical AB’s (publ), (Nasdaq First North Premier Growth Market: ISOFOL), (“Isofol or the
Isofol announces its intention to carry out a fully guaranteed preferential rights issue of approximately SEK 400 million and a potential over-allotment option of up to approximately SEK 100 million
GOTHENBURG, Sweden, April 28, 2021 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), hereby announces that
Isofol receives recommendation from iDSMB to complete the global Phase III AGENT study for market registration as planned with 440 patients
GOTHENBURG, Sweden, March 19, 2021 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that
Isofol announces licensing agreement for Paladin Labs Inc. to commercialize arfolitixorin in Canada
GOTHENBURG, Sweden, November 2, 2020 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) is pleased
Isofol enters licensing agreement with Solasia to develop and commercialize arfolitixorin in Japan
GOTHENBURG, Sweden, August 13, 2020 – Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) today announced
Isofol’s rights issue oversubscribed
GOTHENBURG, Sweden, June 3, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the
Isofol publishes prospectus in connection with the fully guaranteed preferential rights issue of approximately SEK 150 million
GOTHENBURG, Sweden, May 14, 2020 – Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the